ChemoINTEL accurately predicts patient response to chemotherapy and delivers more precise clinically validated data to treating physicians sooner.
Based on foundational work done at Vanderbilt University, ChemoINTEL is an entirely new category of chemo sensitivity assay. ChemoINTEL has produced accurate drug induced apoptotic response in cell lines, demonstrating reproducibility, specificity and sensitivity to successfully predict outcomes. ChemoINTEL measures in vitro apoptotic response of a patient’s tumor to chemotherapy drugs using multiple biochemical and morphologic apoptotic markers within single cells continuously over a 48 hours. ChemoINTEL provide physicians with a report of predicted patient clinical response to a panel of chemotherapy drugs as “Sensitive” and “Non-Sensitive” within 72 hours of sample receipt.
Prior to ChemoINTEL chemosensitivity assays were based on a single endpoint measure of growth inhibition and/or cell death made on cultured patient tumor cells or the development of mouse xenograph models to measure tumor sensitivity to chemotherapy drugs. These assays provide less specific data and take much longer to report (up to 6 months).
Foundational research on the MICK Assay the predecessor to ChemoINTEL is summarized by the published articles below.
RESEARCH (click on PDF icons or file name):
Salom, E., Penalver, M., Homesley, H., Burrell, M., Garrett, A., Presant, C. A., & Rutledge, J. (2012). Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. Journal of Translational Medicine, 10(62), 1-8.
Bosserman, L. D., Rajurka, S. P., Rogers, K., Davidson, D. C., Chernick, M., Hallquist, A., Malouf, D., & Presant, C. A. (2012). Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival with oncologist treatment decisions and patient response and survival. Cancer, 118, 4877-4883.
Strickland., S. A., Raptis, A., Hallquist, A., Rutledge, J., Chernick, M., Perree, M., Tablott, M. S., & Presant, C. A. (2013). Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. Leukemia & Lymphoma, 54(3), 528-534.
Bosserman, L. D., Rogers, K., Willis, C., Davidson, D., Whitworth, P., Karimi, M., Upadhyaya, G., Rutledge, J., Hallquist, A., Perree, M., & Presant, C. A. (2015). Application of a Drug-Induced Apoptosis Assay to Identify Treatment Strategies in Recurrent or Metastatic Breast Cancer.PLoS One, 10(5), doi: 10.1371/journal.pone.0122609
Ballard, K. S., Homesley, H. D., Hodson, C., Presant, C. A., Rutledge, J., Hallquist, A., & Perree, M. (2010) Endometrial Carcinoma In-Vitro Chemosensitivity Testing of Single and Combination Chemotherapy Regimens Using the Novel Microculture Kinetic (MiCK) Apoptosis Assay: Implications for Endometrial Cancer Treatment. Journal of Gynecology Oncology, 21(1),45-49, doi: 10.3802/jgo.2010.21.1.45